Everolimus Limits Aortic Aneurysm in the Apolipoprotein E–Deficient Mouse by Downregulating C-C Chemokine Receptor 2 Positive Monocytes

Objective—We aimed to determine the effect of mechanistic target of rapamycin inhibitor everolimus on abdominal aortic aneurysm within the angiotensin II (A2)-infused apolipoprotein E–deficient mouse model. Approach and Results—Abdominal aortic aneurysm was induced via subcutaneous infusion of A2. Flow cytometry demonstrated increased circulating and aortic C-C chemokine receptor 2 (CCR2) monocytes during A2 infusion. The number of CCR2 monocytes present within the aorta was positively correlated with suprarenal aortic diameter. Simultaneous infusion of everolimus via a second subcutaneous osmotic micropump inhibited A2-induced aortic dilatation. Using flow cytometry and Western blot analysis, decreased aortic dilatation was associated with reduced development of CCR2 bone marrow monocytes, fewer numbers of circulating CCR2 monocytes, and lower aortic CCR2 concentration. In vitro, everolimus inhibited A2-stimulated production of interferon (IFN)-&ggr; and IFN&ggr;-induced CCR2 expression in apolipoprotein E–deficient mouse bone marrow monocytes. Further, everolimus diminished IFN&ggr;/lipopolysaccharide-stimulated M1 polarization in apolipoprotein E–deficient mouse bone marrow monocyte–differentiated macrophages. Conclusions—Systemic administration of everolimus limits aortic aneurysm in the A2-infused apolipoprotein E–deficient mouse model via suppressed development of bone marrow CCR2 monocytes and reduced egress of these cells into the circulation.

[1]  H. Young,et al.  MCP‐1/CCR2 interactions direct migration of peripheral B and T lymphocytes to the thymus during acute infectious/inflammatory processes , 2012, European journal of immunology.

[2]  P. Jabbour,et al.  Macrophage imbalance (M1 vs. M2) and upregulation of mast cells in wall of ruptured human cerebral aneurysms: preliminary results , 2012, Journal of Neuroinflammation.

[3]  M. Rudnicki,et al.  The mTOR-inhibitor rapamycin mediates proteinuria in nephrotoxic serum nephritis by activating the innate immune response. , 2012, American journal of physiology. Renal physiology.

[4]  J. Golledge,et al.  Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model. , 2012, The American journal of pathology.

[5]  F. Moll,et al.  Osteoprotegerin Is Associated With Aneurysm Diameter and Proteolysis in Abdominal Aortic Aneurysm Disease , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[6]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[7]  M. Horton,et al.  Regulation of immune responses by mTOR. , 2012, Annual review of immunology.

[8]  X. Bai,et al.  Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. , 2012, Cancer research.

[9]  B. Nandi,et al.  Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis infection , 2011, The Journal of experimental medicine.

[10]  K. Fujiu,et al.  Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. , 2011, The Journal of clinical investigation.

[11]  J. Golledge,et al.  Current status of medical management for abdominal aortic aneurysm. , 2011, Atherosclerosis.

[12]  C. Teunissen,et al.  Classically and alternatively activated bone marrow derived macrophages differ in cytoskeletal functions and migration towards specific CNS cell types , 2011, Journal of Neuroinflammation.

[13]  Ryan M. O’Connell,et al.  A MyD88-dependent IFNγR-CCR2 signaling circuit is required for mobilization of monocytes and host defense against systemic bacterial challenge , 2011, Cell Research.

[14]  M. Yılmaz,et al.  The Role of the CCR2 Gene Polymorphism in Abdominal Aortic Aneurysms , 2011, Angiology.

[15]  A. Brasier,et al.  Aortic Adventitial Fibroblasts Participate in Angiotensin-Induced Vascular Wall Inflammation and Remodeling , 2010, Journal of Vascular Research.

[16]  P. Quax,et al.  Systemic MCP1/CCR2 blockade and leukocyte specific MCP1/CCR2 inhibition affect aortic aneurysm formation differently. , 2010, Atherosclerosis.

[17]  J. Golledge,et al.  Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors? , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[18]  D. Milewicz,et al.  Thoracic aortic disease in tuberous sclerosis complex: molecular pathogenesis and potential therapies in Tsc2+/- mice. , 2010, Human molecular genetics.

[19]  L. Rénia,et al.  TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. , 2010, The Journal of clinical investigation.

[20]  A. Daugherty,et al.  Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE−/− mice , 2010, Clinical science.

[21]  D. Milewicz,et al.  An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. , 2009, The Journal of clinical investigation.

[22]  H. Matsubara,et al.  Bone Marrow Angiotensin AT1 Receptor Regulates Differentiation of Monocyte Lineage Progenitors From Hematopoietic Stem Cells , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[23]  J. Golledge,et al.  Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm , 2009, BMC Genomics.

[24]  T. V. Berkel,et al.  Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice. , 2009, Journal of vascular surgery.

[25]  Yi Li,et al.  Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. , 2009, The American journal of pathology.

[26]  F. Geissmann,et al.  Blood monocytes: development, heterogeneity, and relationship with dendritic cells. , 2009, Annual review of immunology.

[27]  D. Praticò,et al.  Low‐dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor , 2009, British journal of pharmacology.

[28]  A. Corsini,et al.  Everolimus Inhibits Monocyte/Macrophage Migration in Vitro and Their Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits , 2009, Journal of Pharmacology and Experimental Therapeutics.

[29]  S. Germain,et al.  Modulation of Macrophage Activation State Protects Tissue from Necrosis during Critical Limb Ischemia in Thrombospondin-1-Deficient Mice , 2008, PloS one.

[30]  J. Edwards,et al.  Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.

[31]  M. Cavasin,et al.  Role of Inflammation in the Development of Renal Damage and Dysfunction in Angiotensin II–Induced Hypertension , 2008, Hypertension.

[32]  F. Geissmann,et al.  Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T‐cell responses , 2008, Immunology and cell biology.

[33]  D. Teupser,et al.  Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. , 2008, Atherosclerosis.

[34]  J. Mactaggart,et al.  Deletion of CCR2 but not CCR5 or CXCR3 inhibits aortic aneurysm formation. , 2007, Surgery.

[35]  S. Schreml,et al.  mTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells. , 2007, International immunopharmacology.

[36]  D. Renlund,et al.  Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[37]  M. Mack,et al.  Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. , 2007, The Journal of clinical investigation.

[38]  C. Tsang,et al.  Targeting mammalian target of rapamycin (mTOR) for health and diseases. , 2007, Drug discovery today.

[39]  N. Sonenberg,et al.  Regulatory Effects of Mammalian Target of Rapamycin-activated Pathways in Type I and II Interferon Signaling* , 2007, Journal of Biological Chemistry.

[40]  G. D. De Meyer,et al.  Everolimus-Induced mTOR Inhibition Selectively Depletes Macrophages in Atherosclerotic Plaques by Autophagy , 2007, Autophagy.

[41]  A. Webster,et al.  Target of Rapamycin Inhibitors (Sirolimus and Everolimus) for Primary Immunosuppression of Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Trials , 2006, Transplantation.

[42]  Peter Libby,et al.  Inflammation and cellular immune responses in abdominal aortic aneurysms. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[43]  R. Stahl,et al.  Angiotensin II-Induced Mononuclear Leukocyte Interactions with Arteriolar and Venular Endothelium Are Mediated by the Release of Different CC Chemokines1 , 2006, The Journal of Immunology.

[44]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[45]  A. Zernecke,et al.  Crucial Role of the CCL2/CCR2 Axis in Neointimal Hyperplasia After Arterial Injury in Hyperlipidemic Mice Involves Early Monocyte Recruitment and CCL2 Presentation on Platelets , 2004, Circulation research.

[46]  D. Carey,et al.  Rapamycin suppresses experimental aortic aneurysm growth. , 2004, Journal of vascular surgery.

[47]  L. Shaw,et al.  Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses , 2003, Transplantation.

[48]  K. Takeda,et al.  Rho-Kinase Mediates Angiotensin II-Induced Monocyte Chemoattractant Protein-1 Expression in Rat Vascular Smooth Muscle Cells , 2001, Hypertension.

[49]  J. Wilcox,et al.  CC Chemokine Receptor 2 Is Required for Macrophage Infiltration and Vascular Hypertrophy in Angiotensin II–Induced Hypertension , 2000, Hypertension.

[50]  T. Starzl,et al.  Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. , 1994, Transplantation.

[51]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .